(Q37938689)

25 August 2017

1 reference

title

Mineral and bone disorders in children with chronic kidney disease (English)

1 reference

25 August 2017

Claus Peter Schmitt

1

1 reference

25 August 2017

Otto Mehls

series ordinal

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

27 September 2011

1 reference

Nature Reviews Nephrology

25 August 2017

published in

1 reference

25 August 2017

volume

7

1 reference

25 August 2017

issue

11

1 reference

25 August 2017

page(s)

624-634

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2011.139

25 August 2017

exact match

0 references

cites work

Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

The bone and mineral disorder of children undergoing chronic peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Contribution of intestine, bone, kidney, and dialysis to extracellular fluid calcium content

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

The physiologic development of fetuin-a serum concentrations in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Parathyroid hormone levels in pubertal uremic adolescents treated with growth hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Parathyroid hormone and growth in children with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Bone histomorphometry in children prior to commencing renal replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Daily on line haemodiafiltration promotes catch-up growth in children on chronic dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Value of the new bone classification system in pediatric renal osteodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Non-traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Endothelial progenitor cells and endothelial vesicles - what is the significance for patients with chronic kidney disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

CYP24A1 and kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Clinical Significance of FGF-23 in Patients with CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Bone assessment in children with chronic kidney disease: data from two new bone imaging techniques in a single-center pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Effects of sex, race, and puberty on cortical bone and the functional muscle bone unit in children, adolescents, and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Normative data for iliac bone histomorphometry in growing children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Vitamin D insufficiency and effect of cholecalciferol in children with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

A bimodal association of vitamin D levels and vascular disease in children on dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Chronotherapy of high-dose active vitamin D3 in haemodialysis patients with secondary hyperparathyroidsm: a repeated dosing study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Lanthanum deposition in a dialysis patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Cinacalcet is efficacious in pediatric dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Precocious puberty and unlicensed paediatric drugs for severe hyperparathyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Extracellular calcium and parathyroid hormone-related peptide signaling modulate the pace of growth plate chondrocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Parathyroid hormone-related peptide delays terminal differentiation of chondrocytes during endochondral bone development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

A hypocalcemic child with a novel activating mutation of the calcium-sensing receptor gene: successful treatment with recombinant human parathyroid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

A family with autosomal dominant hypocalcaemia with hypercalciuria (ADHH): mutational analysis, phenotypic variability and treatment challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Cinacalcet does not affect longitudinal growth but increases body weight gain in experimental uraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Middle-term use of Cinacalcet in paediatric dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Long-Term Survival of Children with End-Stage Renal Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Vitamin D deficiency is associated with short stature and may influence blood pressure control in paediatric renal transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

The absorption of dietary phosphorus and calcium in hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Assessment and interpretation of the tubular threshold for phosphate in infants and children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Fetuin-A serum concentrations in healthy children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Growth and PTH in prepubertal children on long-term dialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Correlation among markers of renal osteodystrophy in pediatric hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Comparative study of quantitative ultrasonography and dual-energy X-ray absorptiometry for evaluating renal osteodystrophy in children with chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Bone markers predict cardiovascular events in chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

The peak bone mass concept: is it still relevant?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Limitations of dual x-ray absorptiometry in children with chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Vitamin D deficiency in children with chronic kidney disease: uncovering an epidemic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Pharmacokinetics of vitamin D toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Mortality risk among hemodialysis patients receiving different vitamin D analogs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Vitamin D compounds for people with chronic kidney disease requiring dialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Vitamin D compounds for people with chronic kidney disease not requiring dialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Differential effects of vitamin D receptor activators on vascular calcification in uremic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Effect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Effects of Ca2+ sensing receptor activation in the growth plate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Intermittent administration of parathyroid hormone (1-37) improves growth and bone mineral density in uremic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Rickets in cation-sensing receptor-deficient mice: an unexpected skeletal phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

A novel mutation (E767K) in the second extracellular loop of the calcium sensing receptor in a family with autosomal dominant hypocalcemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Stimulation of the calcium-sensing receptor stabilizes the podocyte cytoskeleton, improves cell survival, and reduces toxin-induced glomerulosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Long-term control of parathyroid hormone and calcium-phosphate metabolism after parathyroidectomy in children with chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.139

Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis.

31 March 2020

1 reference

12 December 2020

Growth in children with chronic renal failure on intermittent versus daily calcitriol

1 reference

12 December 2020

Bone biopsy results and serum bone turnover parameters in uremic children

1 reference

12 December 2020

Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone

1 reference

12 December 2020

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

1 reference

12 December 2020

A novel mechanism for skeletal resistance in uremia

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2011.139

1 reference

25 August 2017

1 reference